IQIYI Inc - ADR vs Tempus AI — how do they compare? IQIYI Inc - ADR trades at $1.02 (market cap $974.67M), while Tempus AI trades at $70.3 (market cap $12.58B). The key difference: Tempus AI is far larger — about 12.9× IQIYI Inc - ADR's market cap, and Tempus AI is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Tempus AI for 22 Days on average.
| IQ | TEM | |
|---|---|---|
Market Cap | $974.67M | $12.58B |
Volume | 4,964,108 | 7,444,569 |
Sector | Media | Broad Market / Factor |
52-Week High | $2.35 | $99.28 |
52-Week Low | $0.86 | $41.55 |
Typical Hold Time | 55 Days | 22 Days |
Enterprise Value | $2.47B | $13.21B |
Signals from Pluang's Aura AI — not financial advice
IQ trades at $1.015, up 0.5% on the day, with a neutral technical signal and bearish moving averages. The company reported a net loss of $206.31 million in 2025 despite beating EPS estimates in recent quarters. Revenue declined to $27.29 billion, and negative profit margins persist. Analyst sentiment is mixed with a 50% buy rating. Recent news highlights iQIYI's focus on AI-driven content, including new titles and revenue-sharing successes.
The outlook is cautious due to revenue contraction and recurring losses, though AI initiatives offer growth potential. Key risks include competitive pressures in streaming and reliance on Chinese market dynamics. Institutional ownership trends and earnings performance in upcoming quarters will be critical for stock direction.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →